T-cell therapy targeting CD38, has been administered to a patient with relapsed/refractory acute myeloid leukemia (R/R AML) in an investigator-initiated trial. 1 The investigator-initiated trial of KJ ...

About THANK-uCAR® THANK (Target to Hinder the Attack of NK cells)-uCAR® is CARsgen's proprietary technology to generate allogeneic CAR-T cells with improved expansion and persis ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...

Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express ...

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT).

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies ...

Central to the pathogenesis of VaD are cerebrovascular endothelial cell (CEC) dysfunction, blood-brain barrier (BBB) disruption, and neuroinflammation. CD38, an enzyme involved in neuroinflammation ...

SHANGHAI, China I January 20, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and ...